Three cancer therapies were among the first two batches of drugs to receive vouchers through a new FDA program.
In a phase 2 trial, firsekibart — an IL-1 beta antibody — outperforms colchicine in preventing acute gout flares over 12 ...
The long-awaited Canadian approval of lecanemab has shifted physicians’ approach to Alzheimer’s disease, addressing previous ...
Older, impulsive teens with prior substance use are more likely to be open to vaping or smoking, while strong parental ...
An expert panel calls the requirement for tuberculosis testing before prescribing IL-17 and IL-23 biologics for psoriasis an ...
A recent study validates that combining genetic and clinical data can predict the risk for pulmonary fibrosis in patients ...
Individuals with systemic sclerosis have a higher risk for hematologic malignancies than those without the condition, with ...
A French-American team reports that Carba1 prevents chemotherapy-induced neuropathy in preclinical models while preserving ...
A meta-analysis shows varying effectiveness of treatments in restoring smell in patients with chronic rhinosinusitis with ...
A large number of young adults in the US are turning to generative AI tools for mental health support, with more than 90% ...
Patients with or without rheumatoid arthritis treated with immune checkpoint inhibitors show no significant difference in the ...
Diagnostic delays stem from uneven access to specialist testing, lack of reliable biomarkers, and symptom overlap with common mental health and attention disorders.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback